Paul Streck

Paul Streck discloses dealings in 2 companies, chiefly PepGen Inc. and Albireo Pharma, Inc. We count 7 filings; the first trade dates from 19 December 2022 and the latest from 4 March 2026.

Both buying and selling appear: 1 purchase worth €9,134, against 1 sale worth €9,829. On balance, insiders were net sellers of €694. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 share grants. 2026 to date brings no purchases and 1 sale.

The latest filing, published on 6 March 2026, reports an open-market sale of €9,829 in PepGen Inc. The clock since the last published purchase (2 June 2025) now reads 503 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.